News

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

  • Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
    05/20/2025

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

  • ASHBURN, Va., May 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.
    05/14/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Quoin Pharmaceuticals, Ltd. (QNRX) can sell. Click on Rating Page for detail.

The price of Quoin Pharmaceuticals, Ltd. (QNRX) is 9.2 and it was updated on 2025-07-11 13:00:27.

Currently Quoin Pharmaceuticals, Ltd. (QNRX) is in undervalued.

News
    
News

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

  • ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
    Wed, Apr. 30, 2025

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

  • Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
    Thu, Apr. 10, 2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

  • ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application of QRX003, the subject's skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. In addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. Importantly, with the patient's pruritus or itch almost completely eliminated, she continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in the patient's life. No adverse events have been reported to date after 6 weeks of whole body treatment with QRX003.
    Wed, Apr. 02, 2025

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

  • ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announced it has filed a U.S. patent application for novel topical formulations to treat a number of skin diseases, including Netherton Syndrome (NS). Quoin's lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin's open Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). QRX003 is also currently being tested in a pediatric NS patient at the Children's Hospital in Dublin, Ireland and the Company intends to expand this study to include additional children with NS in Spain, the United Kingdom and potentially other countries. The Company has recently reported positive initial clinical data from the two open label studies for which data is available. This patent application also includes Peeling Skin Syndrome for which Quoin has an ongoing Investigator Clinical Study in a pediatric patient in New Zealand. There are currently no FDA approved treatments for either Netherton Syndrome or Peeling Skin Syndrome.
    Tue, Mar. 25, 2025

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

  • ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress.
    Thu, Mar. 13, 2025
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

  • ASHBURN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced it has filed U.S. and International patent applications for novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare diseases including microcystic lymphatic malformations, venous malformations and angiofibromas. The products are being developed using Quoin's in-licensed proprietary Invisicare delivery technology. There are currently no FDA approved treatments for either microcystic lymphatic malformations or venous malformations.
  • 03/04/2025

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

  • ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. Dramatic improvement was observed in the patient's disease state with clear visual evidence of skin healing observed after just two weeks of whole-body application of QRX003. No adverse events have been reported to date.
  • 02/27/2025

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

  • ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
  • 02/25/2025

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

  • ASHBURN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the “NETHERTON NOW” campaign to shed light on the profound and poorly understood impacts of Netherton Syndrome, a devastating genetic disease that has been significantly misdiagnosed in the past. It is estimated that up to 20% of babies born with Netherton Syndrome do not survive, highlighting the urgent need for greater awareness and new treatment options.
  • 02/04/2025

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

  • ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome.
  • 01/23/2025

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

  • LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment. Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome.
  • 01/23/2025

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

  • NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company's notable interim data in its ongoing Netherton Syndrome clinical trials.
  • 01/07/2025

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

  • ASHBURN, Va., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces additional positive interim clinical data from one of its ongoing Netherton Syndrome clinical studies.
  • 01/06/2025

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

  • ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), Series F warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs and Series G warrants to purchase an aggregate of up to 15,111,110 ordinary shares represented by 15,111,110 ADSs at a combined purchase price of $0.45 per ADS and associated Series F and Series G warrants. The Series F warrants and Series G warrants will have an exercise price of $0.45 per share, will be exercisable immediately following the date of issuance and will expire in two years and five years, respectively, from their issuance.
  • 12/20/2024

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

  • ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in the skin responsible for the excessive skin shedding associated with this disease.
  • 12/19/2024

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

  • ASHBURN, Va., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies.
  • 12/18/2024

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

  • ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
  • 10/31/2024

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

  • ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction.
  • 09/09/2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

  • Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
  • 08/08/2024

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

  • Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
  • 08/06/2024

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

  • ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024.
  • 08/01/2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

  • ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.
  • 06/25/2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

  • Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases
  • 06/12/2024

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

  • FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
  • 05/09/2024

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

  • ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.
  • 05/02/2024

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

  • Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript
  • 03/14/2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

  • Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints
  • 03/13/2024

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

  • ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
  • 03/07/2024

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?

  • Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
  • 03/05/2024

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

  • LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX). The trials focus on the innovative formulation "QRX003," powered by Skinvisible's Invisicare® proprietary drug delivery technology, to address the challenges of Netherton Syndrome ("NS").
  • 02/14/2024

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

  • NEW YORK, NY, December 13, 2023 – Quoin Pharmaceuticals (Nasdaq:QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments.
  • 12/13/2023

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

  • Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials
  • 12/13/2023

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

  • Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
  • 11/09/2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

  • Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study
  • 11/08/2023

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

  • ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023.
  • 11/03/2023

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

  • Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints
  • 10/24/2023

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

  • Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints
  • 10/24/2023

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

  • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman - Maxim Group Laura Suriel - Alliance Global Partners Operator Good morning.
  • 08/07/2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

  • Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study
  • 08/02/2023

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?

  • Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. According to a filing from Quoin Pharmaceuticals, the company is enacting an ADS ratio change that will switch its stock from one for 5,000 shares to one for 6,000 shares.
  • 07/17/2023

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

  • ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023.
  • 03/02/2023

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

  • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Global Partners Naz Rahman - Maxim Group Operator Good morning and welcome to the Quoin Pharmaceuticals Limited Third Quarter Financial Results and Business Update Call.
  • 11/10/2022

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

  • ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 10, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.
  • 11/01/2022

10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022

  • Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 10/19/2022

7 Penny Stocks To Buy According To Top Wall Street Analysts

  • Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 10/18/2022

Hot Penny Stocks To Watch Today As Stock Market Crash Continues

  • Hot penny stocks to watch today. The post Hot Penny Stocks To Watch Today As Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/20/2022

4 Penny Stocks Making A Comeback In September, Time To Buy?

  • Penny stocks making a comeback to watch this week. The post 4 Penny Stocks Making A Comeback In September, Time To Buy?
  • 09/07/2022

Quoin Pharmaceuticals, Ltd. (QNRX) CEO Michael Myers on Q2 2022 Results - Earnings Call Transcript

  • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2022 Earnings Conference Call August 18, 2022 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Denise Carter - Chief Operating Officer and Director Conference Call Participants Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Good morning and welcome to the Quoin Pharmaceuticals Limited Second Quarter Financial Results and Business Update Call.
  • 08/18/2022

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

  • ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.
  • 08/11/2022

Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?

  • QNRX stock is nearly doubling after the company sought permission to cancel an announcement of share sales.  The post Why Is Quoin Pharmaceuticals (QNRX) Stock Up 93% Today?
  • 07/01/2022

Best Penny Stocks To Buy Right Now? 4 To Watch Under $1

  • Penny stocks under $1 to watch. The post Best Penny Stocks To Buy Right Now?
  • 07/01/2022

Penny Stocks To Buy Now? 4 To Watch With Big News

  • Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 06/06/2022

Why Quoin Pharmaceuticals Stock Is Trading Higher

  • Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003. QRX003 is Quoin's investigational product for.
  • 04/25/2022

Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today

  • What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?
  • 01/07/2022

Best Penny Stocks to Buy as 2021 Ends? 3 to Watch Right Now

  • Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?
  • 12/21/2021
Unlock
QNRX Ratings Summary
QNRX Quant Ranking